Table 2 Plasma concentrations of inflammation parameters before and after LPS infusion.

From: A randomized placebo-controlled trial in healthy volunteers examining the effects of acetaminophen and NO-acetaminophen NCX 701 in human endotoxemia

   

Basal concentrations

Peak concentrations

Pharmacodynamic Marker

Treatment

n

Mean (SD)

Mean (SD)

TNF-alpha (pg/ml)

Placebo

10

3 (3)

136 (211)

 

Acetaminophen

10

2 (3)

76 (58)

 

NCX701 (1 g)

10

1 (1)

55 (32)

 

NCX701 (2 g)

10

1 (1)

103 (55)

Interleukin-6 (pg/ml)

Placebo

10

1 (0.4)

580 (361)

 

Acetaminophen

10

1 (1)

350 (296) *

 

NCX701 (1 g)

10

2 (4)

349 (256) **

 

NCX701 (2 g)

10

1 (1)

671(228)

Interleukin-8 (pg/ml)

Placebo

10

10 (0)

413 (240)

 

Acetaminophen

10

10 (0)

427 (229)

 

NCX701 (1 g)

10

10 (0)

305 (186)

 

NCX701 (2 g)

10

10 (0)

445 (235)

MCP-1 (pg/ml)

Placebo

10

141 (44)

12,536 (6347)

 

Acetaminophen

10

149 (40)

10,254 (6360)

 

NCX701 (1 g)

10

159 (45)

10,121(3674)

 

NCX701 (2 g)

10

131 (29(

10,521 (4860)

MMP2 (ng/ml)

Placebo

10

245 (50)

239 (40)

 

Acetaminophen

10

232 (34)

234 (43)

 

NCX701 (1 g)

10

242 (29)

233 (36)

 

NCX701 (2 g)

10

229 (34)

245 (60)

MMP9 (ng/ml)

Placebo

10

38 (12)

329 (227)

 

Acetaminophen

10

43 (20)

325 (227)

 

NCX701 (1 g)

10

44 (18)

255 (146)

 

NCX701 (2 g)

10

41 (16)

306 (256)

Elastase (pg/ml)

Placebo

10

9 (3)

18 (7)

 

Acetaminophen

10

9 (2)

13 (4)

 

NCX701 (1 g)

10

11 (7)

16 (10)

 

NCX701 (2 g)

10

11 (3)

17 (5)

WBC (10^9/l)

Placebo

10

6 (1)

11 (4)

 

Acetaminophen

10

5 (1)

9 (2)

 

NCX701 (1 g)

10

6 (2)

11 (2)

 

NCX701 (2 g)

10

5 (1)

10 (2)

  1. *p = 0.02 for NCX701 (2 g) vs. NCX701(1 g).
  2. **p = 0.02 for NCX701 (2 g) vs. acetaminophen.
  3. TNF-alpha: tumor necrosis factor-alpha.
  4. MCP-1: monocyte chemoattractant protein-1.
  5. MMP2: matrix metalloproteinase 2.
  6. MMP9: matrix metalloproteinase 9.
  7. WBC: white blood cell.
Back to article page